Skip to main content

Patient Search

KaCrole Higgins was diagnosed with breast cancer in 2020. “In May 2020, I found a lump in my breast. I cried. By June, it was diagnosed as breast cancer, triple positive, stage 1A. While getting this cancer diagnosis was devastating, it also became an opportunity. Suddenly, the cancer gave me clarity. It gave me clarity about what was important, what was good in my life, what was toxic in my life, and what I needed to do.” Click below to read more of KaCrole’s story

https://momentum.vicc.org/2022/04/cancer-gave-me-clarity/

If Landon Ryan had been diagnosed with bilateral retinoblastoma 10, 20 or 30 years ago, she might not be here today with nearly perfect vision.Thanks to recent improvements in the treatment for this rare form of cancer that almost exclusively affects children under the age of 5, the diagnosis had the power to change Landon’s life when she was 11 months old, but not to take it — or her eyesight. Click below to learn more about Landon and her story.

https://momentum.vicc.org/2022/04/brighter-outlook/
Displaying 1 - 10 of 25

Study explores new urinary tract infection treatment

Submitted by sobecksm on

Vanderbilt's Neil Osheroff, PhD, is part of an international research collaboration resulting in what is on track to be the first new antibiotic treatment for uncomplicated urinary tract infections in more than 20 years.

https://news.vumc.org/2023/02/02/study-explores-new-urinary-tract-infection-treatment/
VUMC News & Communications
Locked

Clamping Down the Metabolic Pipeline to B Cells

Submitted by robbikm2 on

New research shows the nutritive needs of B cells are more flexible than previously thought, which could enable researchers to steer antibody production in the lymph nodes and spleen to better combat autoimmunity. Patients with high-risk diseases of the immune system, particularly systemic lupus erythematosus, could stand to benefit from the research findings. The study led by Mark Boothby, MD, and published in the Journal of Immunology, provides details regarding how murine B cells use different sugars as they mature into antibody-producing cells

https://discoveries.vanderbilthealth.com/2024/02/clamping-down-the-metabolic-pipeline-to-b-cells/
Vanderbilt Health
Locked

Research Snapshot: DNA replication discovery opens pathways to understanding and treating cancer, aging and degenerative disease

Submitted by sobecksm on

An international collaboration led by biochemist David Cortez reached revelatory conclusions in exploration of how cells tolerate DNA damage and genome instability. Est. reading time: 2 mins.

https://news.vanderbilt.edu/2023/05/02/research-snapshot-dna-replication-discovery-opens-pathways-to-understanding-and-treating-cancer-aging-and-degenerative-disease/
Marissa Shapiro
Locked

Phase I/II Trial of Gabapentin plus Ketamine for Prevention and Treatment of Acute and Chronic Pain in Locally Advanced Head and Neck Cancer Patients Undergoing Primary or Adjuvant Chemoradiation.

Multiple Cancer Types

Head/Neck, Phase I
I/II
Lockney, Natalie
NCT05156060
VICCHNP2173

Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)

Multiple Cancer Types

This phase II ADC MATCH screening and multi-sub-study treatment trial is evaluating whether biomarker-directed treatment with one of three antibody-drug conjugates (ADCs) (sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan) works in treating patients with solid tumor cancers that have high expression of the Trop-2, nectin-4, or HER2 proteins and that may have spread from where they first started (primary site) to nearby tissue, lymph nodes, or distant parts of the body (advanced) or to other places in the body (metastatic). Precision medicine is a form of medicine that uses information about a person's genes, proteins, and environment to prevent, diagnose, or treat disease in a way that is tailored to the patient. ADCs such as sacituzumab govitecan, enfortumab vedotin, and trastuzumab deruxtecan are monoclonal antibodies attached to biologically active drugs and are a form of targeted therapy. Sacituzumab govitecan is a monoclonal antibody, called sacituzumab, linked to a drug called govitecan. Sacituzumab attaches to a protein called Trop-2 on the surface of tumor cells and delivers govitecan to kill them. Enfortumab vedotin is a monoclonal antibody, enfortumab, linked to an anticancer drug called vedotin. It works by helping the immune system to slow or stop the growth of tumor cells. Enfortumab attaches to a protein called nectin-4 on tumor cells in a targeted way and delivers vedotin to kill them. Trastuzumab deruxtecan is composed of a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug, called deruxtecan. Trastuzumab attaches to HER2 positive tumor cells in a targeted way and delivers deruxtecan to kill them. Personalized treatment with sacituzumab govitecan, enfortumab vedotin, or trastuzumab deruxtecan may be an effective treatment option for patients with advanced or metastatic solid tumors that screen positive for high expression of Trop-2, nectin-4, or HER2, respectively.
Adrenocortical, Bladder, Breast, Cervical, Colon, Dermatologic, Esophageal, GIST, Gastric/Gastroesophageal, Gastrointestinal, Gynecologic, Head/Neck, Kidney (Renal Cell), Liver, Lung, Melanoma, Miscellaneous, Ovarian, Pancreatic, Prostate, Rectal, Sarcoma, Thyroid, Urologic, Uterine
II
Keedy, Vicki
NCT06311214
ETCMD10397

Study Evaluating 89ZrPanitumumab for Assessment of Indeterminate Metastatic and/or Primary Lesion(s) on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma

Head/Neck

Head/Neck
I
Topf, Michael
NCT05747625
VICCHN2279

Self-Management for Head and Neck Lymphedema and Fibrosis [PROMISE Trial]

Head/Neck

The goal of this study is to evaluate the effectiveness of a standardized lymphedema and fibrosis self-management program (LEF-SMP) to improve LEF self-management and reduce LEF-associated symptom burden, functional deficits, and improve quality of life in head and neck cancer (HNC) survivors.
Head/Neck
N/A
Murphy, Barbara
NCT06125743
VICC-EDHAN23569

Neoadjuvant REGN2810 (Cemiplimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck

Head/Neck

Head/Neck
II
Topf, Michael
NCT05929664
VICC-ITHAN23127

An Open-label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of SMP-3124LP in Adults with Advanced Solid Tumors

Multiple Cancer Types

Breast, Head/Neck, Lung, Non Small Cell, Ovarian, Phase I, Uterine
I/II
Eng, Cathy
NCT06526819
VICC-DTPHI23348

A Phase 1/2 Study of REGN7075 (EGFRxCD28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Multiple Cancer Types

Adrenocortical, Bladder, Breast, Cervical, Colon, Esophageal, GIST, Gastric/Gastroesophageal, Gastrointestinal, Gynecologic, Head/Neck, Kidney (Renal Cell), Liver, Lung, Miscellaneous, Non Small Cell, Ovarian, Pancreatic, Phase I, Prostate, Rectal, Urologic, Uterine
I/II
Choe, Jennifer
NCT04626635
VICC-DTPHI24031